Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement

https://doi.org/10.1016/0190-9622(95)90189-2Get rights and content

Abstract

Background: High-dose cyclosporine therapy significantly alleviates psoriasis within 2 to 4 weeks but is associated with a high rate of side effects. Reports are conflicting on the frequency and promptness of relapse after discontinuation of cyclosporine therapy.

Objective: Our purpose was to compare the efficacy and safety of low-dose cyclosporine with that of etretinate and the stability of remission after replacing cyclosporine therapy with topical anthralin during tapering of cyclosporine.

Methods: In a multicenter study 210 patients with moderate to severe chronic plaque-type psoriasis were randomly assigned to treatment with cyclosporine or etretinate. The initial dosages were 2.5 mg/kg/day for cyclosporine and 0.5 mg/kg/day for etretinate, which could be individually adjusted to 5.0 and 0.75 mg/kg/day, respectively. After a treatment phase of 10 weeks (phase 1) patients receiving cyclosporine were again randomly assigned to a group in which cyclosporine was replaced by topical dithranol (anthralin), or to another group in which the drug was tapered during the next 12 weeks (phase 2). All patients treated with etretinate discontinued therapy after 10 weeks and used topical dithranol.

Results: Mean Psoriasis Area and Severity Index decreased by 71% in the cyclosporine group and by 47% in the etretinate group during phase 1. After 10 weeks of treatment 47% of the patients treated with cyclosporine and 10% of those treated with etretinate showed a reduction of more than 80% in skin involvement. Sixty-four percent of the cyclosporine group and 48% of the etretinate group did not require an increase in the initial dosage, resulting in a mean daily dose of 3.0 and 0.53 mg/kg, respectively. There was significant alleviation of nail involvement and joint complaints in both groups. In phase 2 the increase in mean Psoriasis Area and Severity Index and the incidence of relapse were significantly higher in patients in whom cyclosporine was discontinued and replaced by dithranol than in patients in whom cyclosporine was tapered or who were pretreated with etretinate. During treatment four patients from the cyclosporine group and three patients of the etretinate group discontinued the study because of side effects.

Conclusion: Low-dose short-term cyclosporine therapy for psoriasis is, in comparison with etretinate, highly effective and well tolerated. Individually adjusted cyclosporine therapy allows the majority of patients to continue the low dosage of 2.5 mg/kg/day and still achieve a good clinical response. Remission can be better preserved by tapering the drug than by discontinuing treatment abruptly.

References (56)

  • DJ Margolis et al.

    Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day

    J Am Acad Dermatol

    (1992)
  • RM Grossman et al.

    Hypertriglyceridemia in patients with psoriasis treated with cyclosporine

    J Am Acad Dermatol

    (1991)
  • MJ Stiller et al.

    Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis

    J Am Acad Dermatol

    (1992)
  • G Mockli et al.

    Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist

    J Am Acad Dermatol

    (1990)
  • CN Ellis et al.

    Cyclosporine improves psoriasis in a double-blind study

    JAMA

    (1986)
  • TH Van Joost et al.

    Low-dose cyclosporin A in severe psoriasis: a double-blind study

    Br J Dermatol

    (1988)
  • CN Ellis et al.

    Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial

    N Engl J Med

    (1991)
  • S Reitamo et al.

    A multicenter study of cyclosporin in the plaque form of psoriasis: an interim report

  • F Ippolito et al.

    Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin

    Dermatology

    (1993)
  • G Feutren et al.

    Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis

    Br J Dermatol

    (1990)
  • P Krupp et al.

    Side-effect profile of cyclosporin A in patients treated for psoriasis

    Br J Dermatol

    (1990)
  • P Timonen et al.

    Efficacy of low-dose cyclosporine A in psoriasis: results of dose-findings studies

    Br J Dermatol

    (1990)
  • MA De Rie et al.

    Low-dose cyclosporin A (1, 2 or 3 mg/kg/day) in a large series of moderate psoriasis patients: preliminary results [Abstract]

    J Invest Dermatol

    (1989)
  • JD Bos

    The pathomechanisms of psoriasis: the skin immunesystem and cyclosporin

    Br J Dermatol

    (1988)
  • JF Borel

    Mechanism of action and rationale for cyclosporin A in psoriasis

    Br J Dermatol

    (1990)
  • CS Munro et al.

    The mode of action of cyclosporin

    Drug Invest

    (1990)
  • K Norrby

    Cyclosporine is angiostatic

    Experientia

    (1992)
  • G Mahrle

    Rationale für eine Sandimmun-Therapie der Psoriasis

    Z Hautkr

    (1991)
  • Cited by (154)

    • Nail Psoriasis

      2022, Actas Dermo-Sifiliograficas
    • Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus

      2019, Journal of the American Academy of Dermatology
      Citation Excerpt :

      Acitretin should be initiated at 0.2-0.4 mg/kg for >6 months or until at least a moderate improvement is documented.38,56,61-64 Cyclosporine is only recommended for short-term treatment under monitoring (until moderate improvement has been documented) in doses of 3-5 mg/kg.63,65-70 Methotrexate can be employed in doses up to 15 mg/week, with proper monitoring, and with or without folic acid (according to the country's regulations) for the treatment of nail psoriasis until at least moderate improvement has been documented.38,56,62,63,70,71

    • Tips to Treat the 5 Most Common Nail Disorders. Brittle Nails, Onycholysis, Paronychia, Psoriasis, Onychomycosis.

      2015, Dermatologic Clinics
      Citation Excerpt :

      If the nail plate is thin and fragile, it is better not to use acitretin because it could worsen the condition. Subcutaneous methotrexate (15 mg per week) and a low dosage of oral cyclosporin (2.5 mg/kg/d) have also been used with success.37,38 The former seems to give better results for nail matrix psoriasis, the latter for nail bed psoriasis.

    • Computer-Aided Diagnosis Based on DenseNet201 Architecture for Psoriasis Classification

      2024, EAI/Springer Innovations in Communication and Computing
    View all citing articles on Scopus

    Supported by Sandoz AG, Nürnberg.

    Additional contributors are listed at the end of this article.

    View full text